Cao Buqing, Yu Wenhong, Diao Zhihong, Ma Zhenli, Yan Shineng, Yang Lihua, Huang Xiaoqun, Yang Jingmei
Department of Laboratory Medicine, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China.
Department of Laboratory Medicine, The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, Nanning, China.
Biomark Med. 2025 Apr;19(8):277-286. doi: 10.1080/17520363.2025.2483153. Epub 2025 Apr 2.
This study investigates the diagnostic potential of serum Kallikrein-related peptidase 8 (KLK8) in detecting left ventricular hypertrophy (LVH).
A total of 62 hypertensive patients with LVH, 60 without LVH, and 60 healthy controls were analyzed. LVH was defined by echocardiography using LVMI thresholds (>95 g/m for females, >115 g/m for males). Serum KLK8 levels were measured via ELISA, and receiver operating characteristic (ROC) curve analysis assessed its diagnostic performance.
KLK8 levels were significantly higher in hypertensive patients with LVH (8.59 ± 1.59 ng/mL) than in those without LVH (5.80 ± 1.35 ng/mL) and healthy controls (3.68 ± 0.82 ng/mL). KLK8 positively correlated with blood pressure and cardiac structural parameters, including IVST, LVPWT, and LVEDD. ROC analysis revealed high sensitivity and specificity, indicating KLK8's potential as a biomarker for early LVH detection in hypertension.
In hypertensive patients, KLK8 demonstrates good diagnostic value in predicting LVH.
本研究探讨血清激肽释放酶相关肽酶8(KLK8)在检测左心室肥厚(LVH)方面的诊断潜力。
共分析了62例患有LVH的高血压患者、60例无LVH的高血压患者和60例健康对照者。通过超声心动图使用左心室质量指数(LVMI)阈值(女性>95 g/m²,男性>115 g/m²)来定义LVH。通过酶联免疫吸附测定(ELISA)测量血清KLK8水平,并通过受试者工作特征(ROC)曲线分析评估其诊断性能。
患有LVH的高血压患者的KLK8水平(8.59±1.59 ng/mL)显著高于无LVH的高血压患者(5.80±1.35 ng/mL)和健康对照者(3.68±0.82 ng/mL)。KLK8与血压以及心脏结构参数(包括室间隔厚度(IVST)、左心室后壁厚度(LVPWT)和左心室舒张末期内径(LVEDD))呈正相关。ROC分析显示出高敏感性和特异性,表明KLK8有潜力作为高血压患者早期LVH检测的生物标志物。
在高血压患者中,KLK8在预测LVH方面具有良好的诊断价值。